# QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa

> **NCT07417917** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 102 (estimated)

## Conditions studied

- Adults With Moderate-to-severe Hidradenitis Suppurativa

## Interventions

- **DRUG:** QLS12010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07417917
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-05
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07417917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07417917, "QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07417917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*